Overview

A Sickle CEll Disease ComplicatioN Trial

Status:
Unknown status

Trial end date:
2020-12-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to assess the efficacy of SC411 in reducing the number of sickle cell crisis (SCC) events in sickle cell disease (SCD) subjects receiving SC411 compared to those subjects receiving placebo.

Phase:

Phase 3

Details

Lead Sponsor:

Micelle BioPharma Inc
Sancilio and Company, Inc.